PSM/SH2-B has been described as a cellular partner of the FceRI receptor, insulin receptor (IR), insulin-like growth factor-I (IGF-I) receptor (IGF-IR), and nerve growth factor receptor (TrkA). A function has been proposed in neuronal dierentiation and development but its role in other signaling pathways is still unclear. To further elucidate the physiologic role of PSM we have identi®ed additional mitogenic receptor tyrosine kinases as putative PSM partners including platelet-derived growth factor (PDGF) receptor (PDGFR) beta, hepatocyte growth factor receptor (Met), and ®broblast growth factor receptor. We have mapped Y740 as a site of PDGFR beta that is involved in the association with PSM. We have further investigated the putative role of PSM in mitogenesis with three independent experimental strategies and found that all consistently suggested a role as a positive, stimulatory signaling adapter in normal NIH3T3 and baby hamster kidney ®broblasts. (1) PSM expression from cDNA using an ecdysone-regulated transient expression system stimulated PDGF-BB-, IGF-I-, and insulin-but not EGF-induced DNA synthesis in an ecdysone dose-responsive fashion; (2) Microinjection of the (dominant negative) PSM SH2 domain interfered with PDGF-BB-and insulin-induced DNA synthesis; and (3) A peptide mimetic of the PSM Prorich putative SH3 domain-binding region interfered with PDGF-BB-, IGF-I-, and insulin-but not with EGFinduced DNA synthesis in NIH3T3 ®broblasts. This experiment was based on cell-permeable fusion peptides with the Drosophila antennapedia homeodomain which eectively traverse the plasma membrane of cultured cells. These experimental strategies independently suggest that PSM functions as a positive, stimulatory, mitogenic signaling mediator in PDGF-BB, IGF-I, and insulin but not in EGF action. This function appears to involve the PSM SH2 domain as well as the Pro-rich putative SH3 domain binding region. Our ®ndings support the model that PSM participates as an adapter in various mitogenic signaling mechanisms by linking an activated (receptor) phospho-tyrosine to the SH3 domain of an unknown cellular partner. Oncogene (2000) 19, 39 ± 50.
Introduction
The platelet-derived growth factor (PDGF) family represents key mitogenic and chemotactic factors that have been exploited by the Simian sarcoma virus v-sis oncogene which results in altered PDGF expression (Water®eld et al., 1983) . Normal cellular PDGF appears in three distinct isoforms as any combination of the PDGF A and B chains which act in paracrine and autocrine mechanisms (Heldin, 1993) . PDGF receptor (PDGFR) signal transduction appears to be a largely membrane delineated event (Hughes et al., 1996) . Two receptor types, alpha and beta, have been identi®ed both of which are bound by PDGF-BB, while PDGF-AA only associates with the alpha receptor (Heldin, 1995) . PDGFR activation induces temporarily ordered cellular responses that begin with intracellular Ca 2+¯u xes and cytoplasmic pH changes within seconds (Cooper and Kazlauskas, 1993) . A profound rearrangement of the cytoskeleton follows which involves changes in actin stress ®ber arrangement and formation of plasma membrane processes such as lammelopedia and microspikes, i.e. membrane rues. The long-term responses include cell proliferation, migration, and dierentiation (Claesson-Welsh, 1996; Hughes et al., 1996) . For at least ten tyrosine autophosphorylation sites in the PDGFR beta cytoplasmic domain, speci®c binding proteins have been identi®ed. Most of these bind to a speci®c phospho-tyrosine motif via an SH2 domain and carry an enzymatic activity or additional protein binding domains such as PH (pleckstrin homology), SH3, Prorich regions individually, or in any combination (Claesson-Welsh, 1996) . Tyrosine 579, 716, 740, 751, 1009 , and 1021 have been implicated in the cell proliferative response to PDGF, while tyrosine 716, 771 and 1021 have been implicated in the cell migration response depending on the cellular background (Claesson-Welsh, 1996) . One major partner, p85 phosphatidylinositol 3'-kinase (PI3K) associates with Y740 and Y751 (Kazlauskas and Cooper, 1989; Fantl et al., 1992; Kazlauskas et al., 1992) . The signaling pathways initiating from the PDGFR beta are clearly redundant and other unidenti®ed mediators are expected to participate in many cellular responses including proliferation and chemotaxis (Higaki et al., 1996) . They likely involve unidenti®ed signaling mediators which have not yet been implicated in PDGF action. One candidate, the signaling mediator PSM is the focus of this report.
PSM has been identi®ed as a mouse protein based on its association with the activated catalytic insulin receptor (IR) domain in a yeast two-hybrid screen (Riedel et al., 1997) . It carries a number of domains including a Pro-rich putative SH3 domain binding region, a pleckstrin homology domain (PH) and a src homology 2 (SH2) domain which suggest a role as a putative signaling mediator. Such a role is also supported by the observation that PSM associates with activated but not with inactive forms of IR (Riedel et al., 1997) . A related sequence termed SH2-B had been identi®ed in the rat based on its association with the FceRI receptor that likely represents a rat homologue of PSM (Osborne et al., 1995) . A variant form of PSM/SH2-B, termed beta has been reported which carries an additional 100 bp of coding region downstream of the SH2 domain based on putative alternative splicing and is predicted to result in a shortened protein product (Riedel et al., 1997; Rui et al., 1997) . This variant was described as a substrate and as a potent cytoplasmic activator of the tyrosine kinase JAK2 in response to growth hormone signaling (Rui et al., 1997; Carter-Su and Smit, 1998; Rui and Carter-Su, 1999 ). An association of PSM/SH2-B was established with the insulin-like growth factor-I (IGF-I) receptor (IGF-IR) that depends on receptor activation and was mapped to phospho-tyrosine sites which are conserved between the insulin and IGF-I receptors (Wang and Riedel, 1998) . For SH2-B beta an association was described with PDGFR in response to PDGF activation which stimulated SH2-B beta phosphorylation on tyrosine, serine, and threonine (Rui and Carter-Su, 1998 ) which was also reported in response to nerve growth factor by kinases within the MEK/ERK cascade (Rui et al., 1999b) . In response to insulin, tyrosine phosphorylation had originally not been observed for any form of PSM (Rui et al., 1997; Wang and Riedel, 1998) but has more recently been reported including a role as a substrate of IR (Kotani et al., 1998; Ahmed et al., 1999) . A related protein termed APS, which is structurally similar to PSM/SH2-B and to Lnk is phosphorylated on tyrosine in response to B-cell receptor activation (Yokouchi et al., 1997) and in response to insulin as a substrate of IR (Moodie et al., 1999) . APS also associates with the activated PDGFR or with c-Cbl and inhibits PDGF-induced mitogenesis . APS inhibits the JAK ± STAT signaling pathway in collaboration with c-Cbl . APS and SH2-B have been implicated as substrates of Trk nerve growth factor receptors TrkB/C, and TrkA, respectively, with a role in developing neurons and neuronal dierentiation (Qian et al., 1998; Rui et al., 1999a) .
In combination, the existing data suggest that PSM/ SH2-B represents a family of putative signaling adapters of two known and additional members including unknown splice variants which belong to a superfamily of signaling mediators. Their physiologic roles involve neuronal dierentiation and development and likely unknown functions in mitogenic signaling pathways and other mechanisms of cell regulation.
To further elucidate the physiologic role of PSM we have tested additional, mitogenic receptor tyrosine kinases as putative PSM partners and have identi®ed the activated forms of PDGFR beta, hepatocyte growth factor receptor (Met), ®broblast growth factor receptor, and nerve growth factor receptor (TrkA) as candidates. We have mapped Y740 as a PDGFR beta site that is involved in the association with PSM. We have further investigated the putative role of PSM in mitogenesis with three independent experimental strategies and found that all consistently suggested a role as a positive, stimulatory signaling adapter in normal NIH3T3 and baby hamster kidney ®broblasts. (1) PSM expression from cDNA using an ecdysone-regulated transient expression system stimulated PDGF-BB-, IGF-I-, and insulin-but not EGF-induced DNA synthesis in an ecdysone doseresponsive fashion; (2) Microinjection of the (dominant-negative) PSM SH2 domain interfered with PDGF-BB-and insulin-induced DNA synthesis; and (3) A peptide mimetic of the PSM Pro-rich putative SH3 domain-binding region interfered with PDGF-BB-, IGF-I-, and insulin-but not with EGF-induced DNA synthesis in NIH3T3 ®broblasts. This experiment was based on cell-permeable fusion peptides with the Drosophila antennapedia homeodomain which effectively traverse the plasma membrane of cultured cells.
These experimental strategies independently suggest that PSM functions as a positive, stimulatory, mitogenic signaling mediator in PDGF-BB, IGF-I, and insulin but not in EGF action. This function appears to involve the PSM SH2 domain as well as the Pro-rich putative SH3 domain binding region. Our ®ndings support the model that PSM participates as an adapter in various mitogenic signaling mechanisms by linking an activated (receptor) phospho-tyrosine to the SH3 domain of an unknown cellular partner.
Results
Association of activated PDGFR beta with cellular PSM or p85 PI3K and interference by the PSM SH2 domain Our earlier studies had identi®ed PSM as a cellular partner of the IR and IGF-IR, compatible with a physiologic role in mitogenesis (Riedel et al., 1997; Wang and Riedel, 1998) . To explore such a putative function further we investigated the association of PSM with other mitogenic receptor tyrosine kinases. First we tested the association of PSM with the PDGFR beta, a major, mitogenic growth factor receptor, in co-precipitation experiments followed by immunoblotting. Normal NIH3T3 ®broblasts were starved to quiescence and stimulated with PDGF-BB before detergent cell lysates were precipitated with a rabbit polyclonal antiserum directed against the PSM SH2 domain (Wang and Riedel, 1998) . Precipitates were separated by SDS ± PAGE, and proteins were identi®ed by immunoblotting with a PDGFR beta-speci®c rabbit polyclonal antibody. A speci®c protein of 190 kD was co-precipitated with PSM antiserum, compatible with the predicted migration of PDGFR beta , which was also identi®ed in immunoblots of cell lysates (Figure 1 ). Co-precipitation was speci®cally observed in response to PDGF-BB stimulation, indicating that cellular PSM associates with activated PDGFR beta in a PDGF-BBdependent fashion. No protein bands were observed in co-precipitation experiments involving pre-immune serum. The fraction of co-precipitated cellular PDGFR beta was comparable to the fraction that co-precipitated with an antiserum directed against p85 PI3K, a dierent PDGFR beta partner, in line with an analogous role of both proteins as mediators downstream of PDGFR beta (Figure 1) .
Complementary experiments were carried out by immunoprecipitation with PDGFR beta-speci®c anti-body followed by immunoblotting with rabbit polyclonal antiserum directed against the PSM SH2 domain. A speci®c major protein band was found to associate with activated PDGFR beta in a strictly PDGF-BB-dependent fashion (Figure 1 ) which had earlier been found to associate with activated IR and IGF-I (Wang and Riedel, 1998) . Similar quantities of a band of identical migration were observed on the same blot following immunoprecipitation with PSM antiserum but not with pre-immune serum, suggesting that our antiserum speci®cally recognizes PSM and that the association between PDGFR beta and PSM is signi®cant. Consequently, both complementary experimental strategies show an eective association of cellular PSM with PDGFR beta in response to PDGF-BB stimulation. The PSM SH2 domain was found to abrogate the association between PDGFR beta and cellular PSM suggesting that the SH2 domain plays a major role in the interaction with PDGFR beta.
Mapping of PSM SH2 domain association to PDGFR Y740
To address whether the PSM SH2 domain was sucient to associate with the PDGFR beta, a glutathione S-transferase (GST) fusion protein representing the SH2 domain and carboxyl terminal amino acids (aa) of PSM was prepared and mixed with detergent cell lysates of TRMP canine kidney epithelial cells which lack endogenous but over-express recombinant PDGFR beta from cDNA. Fusion proteins were precipitated with glutathione sepharose, separated by SDS ± PAGE and identi®ed by immunoblotting with PDGFR beta-speci®c antibody. The PSM SH2 domain was found to eectively associate and co-precipitate Figure 1 Association of activated PDGFR beta with cellular PSM or p85 PI3K and interference by the PSM SH2 domain. Normal NIH3T3 ®broblasts were starved and stimulated with PDGF-BB (+) or were left untreated (7). Detergent cell lysates were immediately separated by SDS ± PAGE (±) or were ®rst immunoprecipitated (IP) with pre-immune (PRE), PSM-speci®c (PSM), p85-speci®c (P85), or receptor-speci®c (PDGFRB) antiserum prior to SDS ± PAGE. During this step puri®ed cellpermeable PSM SH2 domain peptide (SH2) was added to test for interference and compared with a control eluate (C) or a blank sample (±). Proteins were transferred to nitrocellulose and identi®ed by immunoblotting (BLOT) with speci®c antiserum directed against PSM or PDGFR beta. were stimulated with 25 ng/ml PDGF-BB (+) or were left untreated (7) after starvation. Detergent cell lysates were (A) immediately separated by SDS ± PAGE (±), or were ®rst incubated with GST-PSM SH2 domain fusion protein alone (IP), or (B) in addition with (PEPTIDE) or without (±) phospho-peptides representing major autophosphorylation motifs (Y716 or Y740) of PDGFR beta (IP). Complexes were precipitated with glutathione sepharose prior to SDS ± PAGE. Proteins were transferred to nitrocellulose and identi®ed by immunoblotting with PDGFR beta antibody. The position of the receptor (PDGFRB) has been indicated on the right with activated PDGFR beta, strictly in response to PDGF-BB stimulation (Figure 2a ).
This approach was extended to de®ne the PDGFR beta motif that is involved in the association with the PSM SH2 domain. A series of PDGFR beta point mutants lacking any one of the major tyrosine autophosphorylation sites were compared in detergent cell lysates of over-expressing TRMP canine kidney cells. Each lysate was mixed with GST-PSM SH2 domain fusion protein and glutathione sepharose precipitates were analysed by immunoblotting with PDGFR beta-speci®c antibody. All mutants were found to co-precipitate with the PSM fusion protein except for a PDGFR beta mutation at Y740 ( Figure  2a ). These data implicate phospho-tyrosine 740 in the association with the PSM SH2 domain. Whether this PDGFR motif actually associates with the PSM SH2 domain was determined in peptide competition experiments. Phospho-peptides representing Y740 and Y716 as a control were mixed with GST-PSM SH2 domain fusion protein in detergent cell extracts to study their impact on PDGFR beta association. Immunoblotting of glutathione sepharose precipitates with PDGFR beta-speci®c antiserum demonstrated that phospho-peptide Y740 speci®cally interfered with the association between PSM and PDGFR beta ( Figure 2b ). This result indicates that the motif representing phospho-tyrosine 740 competes with PDGFR beta for PSM SH2 domain association and con®rms a role of the sequences around Y740 in PSM binding.
Association of other activated receptor tyrosine kinases with the PSM SH2 domain
Many signaling adapters are shared between various receptor tyrosine kinases, which encouraged us to test whether PSM associates with other growth factor receptors. We evaluated one member of most receptor tyrosine kinase subfamilies (van der Geer et al., 1994) and typically compared activated and non-activated receptors. Of those examples tested in Figure 3 , a clear association with the PSM SH2 domain was observed for the PDGFR beta, hepatocyte growth factor (Met) receptor, ®broblast growth factor receptor, and nerve growth factor receptor (TrkA) (Qian et al., 1998; Rui et al., 1999a) , and as we described earlier for IR and IGF-IR (Riedel et al., 1997; Wang and Riedel, 1998; Kotani et al., 1998) . In contrast, an association could not be demonstrated for epidermal growth factor receptor ( Figure 3 ). The presence of all receptors in cell lysates and their activation had been demonstrated by receptor-speci®c antibodies and phospho-tyrosinespeci®c antibodies, respectively. These results suggest that the employed assay can speci®cally discriminate between dierent receptor tyrosine kinase interactions, and are compatible with a potential role of PSM as a general mitogenic signaling mediator.
Microinjection of dominant-negative PSM SH2 domain interferes with growth factor-mediated DNA synthesis
To demonstrate a role of PSM in mitogenesis speci®cally, we used three independent experimental strategies to interfere with the function of cellular PSM or to enhance the function of PSM by over-expression.
First, we used the GST-PSM SH2 domain fusion protein in a microinjection approach (Sasaoka et al., 1994) . It is expected that the SH2 domain will act like a dominant-negative form of PSM when introduced into cells at high concentration (Gotoh et al., 1995; Northrop et al., 1996) . NIH3T3 ®broblasts overexpressing human IR were starved, stimulated with various growth factors, and the GST-PSM SH2 domain fusion protein was microinjected. The eect on DNA synthesis was evaluated at the single cell level by¯uorescence microscopy analysis of incorporated BrdU. Fetal bovine serum, insulin, and PDGF-BB all stimulated DNA synthesis as judged by the increased Figure 3 Ligand-stimulated receptor tyrosine kinase association with the PSM SH2 domain in cell extracts. Typically the various indicated receptor tyrosine kinases were over-expressed in various cell lines and incubated (+) with the speci®c ligand (Activated) or were left untreated (7). Detergent extracts were immediately separated by SDS ± PAGE (Lysate), or were ®rst mixed with control GST (±), or GST-PSM SH2 domain fusion protein (PSM) and complexes were precipitated with glutathione sepharose prior to SDS ± PAGE. Proteins were transferred to nitrocellulose and identi®ed by immunoblotting with phospho-tyrosine antibodies (pTyr) or with speci®c antibodies directed against the respective receptor tyrosine kinase (Receptor-speci®c). Protein bands have been identi®ed as the respective receptor types shown on the left. IGF-I receptors (IGF-IR) over-expressed in IGF-I receptor genedisrupted R 7 mouse embryo ®broblasts (Miura et al., 1995a,b) had been stimulated with 100 ng/ml IGF-I. Insulin receptors (IR) over-expressed in CHO cells had been stimulated with 100 ng/ml insulin (Myers et al., 1991) . Platelet-derived growth factor receptors (PDGFR) beta over-expressed in TRMP canine epithelial kidney cells had been stimulated with 50 ng/ml PDGF-BB . Hepatocyte growth factor receptor (HGFR)/c-Met experiments were performed with constitutively activated v-Met (+) and a kinase-inactive mutant (7) of v-Met (Rodrigues and Park, 1994) . Constitutively activated (+) Xenopus (Type 1, two Ig loop) FGF receptors (FGFR) had been expressed with the Baculovirus system in Sf9 insect cells; non-stimulated forms (7) were not available. (Brown and Friesel, 1993) . Epidermal growth factor receptors (EGFR) over-expressed in A431 human epidermoid carcinoma cells had been stimulated with 100 ng/ml EGF. TrkA over-expressing NIH3T3 cells had been stimulated with 20 ng/ml 7s nerve growth factor (Muragaki et al., 1995) . The sources of the receptor tyrosine kinases (van der Geer et al., 1994) were gifts from various colleagues as indicated number of¯uorescence-positive cells (Figure 4 ). This remained unaected by microinjection of GST protein alone or a GST fusion protein with the Crk SH2 domain that served as a control for the speci®city of the assay (Blakesley et al., 1996) . Microinjection of the GST-PSM SH2 domain fusion protein typically reduced DNA synthesis to less than 30% of growth factor induced levels ( Figure 4 ). The signi®cant mitogenic response to insulin that is similar to the PDGF-BB response in this experiment is explained by the over-expressed IR levels whereas normal NIH3T3 ®broblasts did not signi®cantly respond to insulin (not shown). The PSM SH2 domain was found to speci®cally block the association of PDGFR beta with cellular PSM but not with p85 PI3K (Figure 1 ) suggesting that the observed interference with mitogenesis is PSM-speci®c and not due to a putative modulation of PI3K activity.
Cell-permeable fusion peptides of the PSM Pro-rich region interfere with PDGF-BB-, IGF-I-, and insulinmediated DNA synthesis
In a second experimental strategy we introduced the Pro-rich amino terminal putative SH3 domain binding region of PSM into ®broblasts with an alternative technique. We employed cell permeable peptides based on a 16 aa peptide of the Drosophila antennapedia homeodomain protein which eectively transfers fusion peptides of up to 100 aa in length into any cell type tested (Prochiantz, 1996) . This approach allowed us to interfere with mitogenesis in large numbers of cultured cells when compared to the microinjection approach. Initially, synthetic antennapedia domain fusion peptides with a 16 aa fragment of the PSM amino terminal Prorich region were biotinylated and incubated with starved NIH3T3 ®broblasts for 10 h. Cells were ®xed, permeabilized, and stained with FITC-conjugated streptavidin. Increased¯uorescence was observed in the cell cytoplasm with increasing fusion peptide concentrations in a dose-responsive fashion. At highest peptide concentrations more than two out of three cells showed easily detectable amounts of cytoplasmic peptide in the microscope (Table 1 ). This experiment indicated that the synthetic PSM peptide eciently traverses across the plasma membrane into the cytoplasm of NIH3T3 ®broblasts.
To evaluate the consequences on mitogenesis, normal NIH3T3 ®broblasts were starved and incubated with various growth factors and increasing doses of synthetic Pro-rich fusion peptide. DNA synthesis was measured by the quanti®cation of incorporated 3 Hthymidine. Most growth factors stimulated DNA Figure 4 Interference of the microinjected PSM SH2 domain with growth factor-mediated DNA synthesis. IR-over-expressing mouse NIH3T3 ®broblasts were starved in 0.1% fetal bovine serum for 16 h, control GST (GST), GST-Crk, or GST-PSM SH2 domain fusion proteins were microinjected into 150 cells per sample, and cells were stimulated with 10% serum, insulin, or PDGF-BB for 16 h. (± ± : non-injected controls). BrdU incorporation was visualized by indirect immuno¯uorescence. Fluorescence-positive cells were counted and the mitogenic response is presented as the fraction of positive cells in response to growth factor stimulation, shown in per cent after the basal BrdU incorporation (10%) had been subtracted. The mean of at least three independent experiments is shown and variations are indicated by error bars Synthetic peptides (RQIKIWFQNRRMKWKK-FPSPPALPPPPP-PSWQ) were biotinylated (ECL, Pharmacia) and serum-free NIH3T3 ®broblasts were incubated with the indicated peptide concentrations for 10 h. Cells were ®xed with 4% paraformaldehyde, permeabilized with 0.5% Triton X-100, blocked with 3% BAS, stained with FITC-conjugated streptavidin, and intracellular immuno¯uorescence was evaluated microscopically. The fraction of positive cells is shown for samples treated with PSM Pro-rich peptide and for control-treated samples Figure 5 Impact of cell-permeable fusion peptides carrying the PSM amino terminal Pro-rich region on growth factor-stimulated DNA synthesis. Mouse NIH3T3 ®broblasts were starved in 0.5% serum-containing medium for 24 h, subsequently incubated with the doses 0, 1, 5, 10, or 20 mg/ml of the PSM fusion peptide (RQIKIWFQNRRMKWKK-FPSPPALPPPPPPSWQ), or with the doses 0, 1, 3 or 10 mg/ml (shown in parentheses) of a control peptide (RQIKIWFQNRRMKWKK) and stimulated with 25 ng/ ml PDGF-BB, 100 ng/ml IGF-I, 100 ng/ml insulin, 100 ng/ml EGF, or left untreated for 18 h. 0.5 mCi [methyl-3 H thymidine] at 3 Tbq/mmol was added for 5 h and acid (10% TCA) precipitated radioactivity was quanti®ed by scintillation spectroscopy. Error bars indicate the variation between duplicate measurements. DNA synthesis in the absence of growth factor has been defined as zero and the growth factor-stimulated increase is shown in per cent synthesis about twofold. For control antennapedia peptides lacking any PSM domain, DNA synthesis remained unchanged at any tested concentration of peptide ( Figure 5 ). Similarly, EGF-stimulated DNA synthesis was not signi®cantly reduced by increasing doses of fusion peptide, compatible with the lack of evidence for a role of PSM in EGF action (Figure 3 ). Increasing doses of fusion peptide resulted in a dosedependent decrease in DNA synthesis down to as little as 5% of stimulated levels in normal NIH3T3 ®broblasts in response to PDGF-BB and IGF-I or in IR over-expressing NIH3T3 ®broblasts in response to insulin ( Figure 5 ). These data suggest that the PSM Pro-rich region participates in PDGF-BB, IGF-I and insulin action, possibly by interacting with the SH3 domain of an unidenti®ed signaling mediator. Both experimental strategies, microinjection of the SH2 domain and introduction of a cell-permeable Pro-rich region are expected to result in dominant-negative forms of PSM. Both were shown to interfere with DNA synthesis. Cellular PSM may therefore function as a positive, stimulatory mitogenic signaling adapter.
Ecdysone-regulated PSM expression results in ecdysone dose-responsive stimulation of growth factor-mediated DNA synthesis
If PSM represents a positive mitogenic signaling mediator, increased expression should stimulate DNA synthesis. To regulate PSM expression we employed an ecdysone-controlled cDNA expression system (Invitrogen) which was introduced into ®broblasts by lipofection. In response to increasing doses of ecdysone, increased expression of two protein bands was observed in immunoblots with PSM rabbit polyclonal antiserum when compared to basal levels in the absence of ecydsone or in cells which had been transfected with a control plasmid (Figure 6a ). Background protein levels are not visible due to the limited cell numbers employed in the transfection assay. The migration of the smaller of the expressed proteins was similar to those observed in untransfected cells at higher concentrations of cell lysate (Figure 1 ) and in earlier studies (Wang and Riedel, 1998) . In addition, a larger, unidenti®ed band of an apparent MW of more than 120 kD was observed which has been addressed in the discussion.
To evaluate the impact of increased PSM expression levels on mitogenesis, NIH3T3 or baby hamster kidney (BHK) ®broblasts were transfected with the expression system, starved, stimulated with various growth factors and PSM expression was induced by varying doses of ecdysone. DNA synthesis was quanti®ed through the incorporation of 3 H-thymidine. All growth factors were found to stimulate DNA synthesis between two and threefold ( Figure 6b ). In the absence of ecdysone or after ecdysone induction of control plasmids, even at the highest dose no change in DNA synthesis was observed. Increasing doses of ecdysone led to a dosedependent increase in DNA synthesis for all growth factors, except EGF, con®rming earlier results which a b Figure 6 Ecdysone-regulated PSM cDNA expression and impact on PDGF-BB, IGF-I, insulin, and EGF-mediated mitogenesis. Mouse NIH3T3 or baby hamster kidney (BHK) ®broblasts were cotransfected with 1 ug/ml of each plasmid of the PSM expression system (PSM) or with a control expression plasmid (Control, C) for 18 h in the presence of Lipofectamine. After a 5 h recovery in complete medium cells were incubated with the indicated concentrations (0, 2, 10 mM) of ecdysone analog ponasterone A [Ecdysone] for 39 h. (a) Detergent cell lysates were analysed by SDS ± PAGE. Proteins were transferred to nitrocellulose and identi®ed by immunoblotting with a speci®c antiserum directed against PSM. The migration of size markers is indicated in kD on the right. (b) Cells were starved in low serum for the last 24 h of the induction period and were subsequently incubated with 25 ng/ ml PDGF-BB, 100 ng/ml IGF-I, 100 ng/ml insulin, 100 ng/ml EGF, or were left untreated. Cells were labeled 18 h later with 0.5 mCi [methyl-3 H thymidine] at 3 Tbq/mmol for 5 h, and acid (10% TCA) precipitated radioactivity was quanti®ed by liquid scintillation spectroscopy. Error bars indicate the variation between duplicate measurements. DNA synthesis in the absence of growth factor has been de®ned as zero and the growth factorstimulated increase is shown in per cent failed to provide evidence for a role of PSM in EGF action (Figures 3 and 5) . Maximum DNA synthesis levels were elevated more than threefold by the highest dose of ecdysone when compared to non-induced levels for PDGF-BB, which also typically showed the highest mitogenic response (Figure 6b ). The signi®cant insulin stimulation of DNA synthesis is explained by the overexpressed IR level in the NIH3T3 ®broblasts employed for this growth factor (Blakesley et al., 1996) . PSM SH2 domain microinjection partially reverts the transformed phenotype of BALB-3T3/A31 M angiosarcoma ®broblasts Based on the suggested functional role of PSM in mitogenesis we investigated whether a microinjection approach of a dominant-negative PSM domain could provide evidence for a putative role in cell transformation. Such a role has been predicted for a critical downstream signaling mediator of the IGF-IR or PDGFR (Baserga, 1995; DeMali et al., 1997) . To examine the eects of PSM on cell transformation, BALB-3T3/A31 ®broblasts were used as a model system to address whether PSM could revert the transformed phenotype (Zvibel and Raz, 1985) . Wild-type cells display highly organized actin stress ®bers in contrast to spontaneously transformed mutants such as clone BALB-3T3/A31/M. This mutant line had been stepwise selected for a tumorigenic and metastatic phenotype in mice (Zvibel and Raz, 1985) and displays a disorganized actin pattern (Figure 7 ). More than 100 cells were microinjected in each of several experiments and the actin distribution was visualized in the¯uorescence microscope by phalloidin staining. More than 80% of wild-type cells displayed highly organized actin stress ®bers that remained unchanged after injection of GST fusion proteins with either the PSM or Grb10 SH2 domain. Microinjection of GST-PSM SH2 into Balb-3T3/A31/M ®broblasts partially restored the organization of actin ®bers in 30% of injected cells, suggesting interference of the PSM SH2 domain with the transformed phenotype (Figure 7 ). This was highly elevated over the background of transformed cells (5%) that displayed an organized actin pattern. Microinjection of a control GST-Grb10 SH2 fusion protein only resulted in a small increase in the cell numbers (to 9%) which displayed some actin organization. Fluorescence images of representative cells are shown in Figure 7 .
Taken together, our data suggest that PSM may play a role in an important mitogenic signaling pathway that is shared by various receptor tyrosine kinases as well as in mechanisms that mediate malignant cell transformation.
Discussion
In this study we have demonstrated eective PSM association with the activated PDGFR beta in response to PDGF-BB stimulation which was blocked by a PSM SH2 domain peptide (Figure 1 ). Of the major tyrosine autophosphorylation sites of PDGFR beta only one, Y740, when mutated, resulted in the lack of association with the PSM SH2 domain (Figure 2a ). Synthetic phospho-peptides representing Y740 interfered with PDGFR beta binding to the PSM SH2 domain ( Figure  2b ) and indicated that the motif around phosphotyrosine Y740 actually binds to PSM. This binding site is shared by p85 PI3K and oers perspectives for putative functions of PSM.
A PDGFR mutant Y751 was found to block the association with p85 PI3K (Kazlauskas and Cooper, 1989 ) and a second site at Y740 was implicated in this function Fantl et al., 1992; Kashishian et al., 1992) . In one direct comparison PDGFR mutants Y751F and Y740F were found to bind only 23 and 3%, respectively, of original PI3K levels (Kazlauskaz et al., 1992) . A PSM SH2 domain peptide, however, did not interfere with the association between PDGFR beta and p85 PI3K (Figure 1 ) which indicates dierences in the mechanisms of PDGFR beta binding between PSM and p85 and the importance of PDGFR beta Y751 in the association with p85. Double PDGFR mutants Y740/751F have repeatedly been employed to maximally abolish p85 PI3K association with PDGFR beta. This strategy was described to interfere with PDGF-BB-mediated DNA synthesis (Valius and Kazlauskas, 1993; Fantl et al., 1992) , activation of p70 S6 kinase (Chung et al., 1994) , membrane ruing and chemotaxis (Wennstroem et al., 1994) , PDGFR tracking (Joly et al., 1994) , and the phosphorylation of focal adhesion kinase (p125FAK) and paxillin (Rankin et al., 1996) . In the case of p70 S6 kinase activation or p125FAK and paxillin phosphorylation, PI3K inhibitors have independently indicated an important role of this enzyme (Chung et al., 1994; Rankin et al., 1996) . However, for some of the other functions that are typically attributed to PI3K, a role of PSM needs to be considered now due to the shared PDGFR beta binding site at Y740 which was abolished in the tested receptor mutants.
A function of PSM in PDGFR beta-mediated mitogenesis is compatible with the earlier studies Figure 7 Microinjection of SH2 domains and consequences on actin ®lament organization in normal and transformed BALB-3T3/A31 ®broblasts. GST fusion proteins with the SH2 domains of PSM or Grb10 were microinjected into parental BALB-3T3/ A31 control cells (WT) and into a (spontaneously mutated and selected) transformed and metastatic variant line Balb-3T3/A31/ M (M) (Zvibel and Raz, 1985) . Cells were cultured in 10% bovine calf serum and actin organization was evaluated after 24 h. Cells were permeabilized with 0.5% Triton X-100, ®xed with 3% formaldehyde and stained with rhodamine-conjugated phalloidin. Control cells had not been injected listed above and is supported by the ®ndings in this report as discussed below. Redundant signaling pathways are expected to exist for PDGFR beta-mediated mitogenesis and have been demonstrated for PDGFR beta-dependent cell transformation. Transforming activity is still observed for PDGFR beta mutants which lack either the binding sites for p85 PI3K or for phospholipase C gamma association but not for mutants which lack both sites (DeMali et al., 1997). A role of PSM in any of the other responses to PDGFR beta activation is unknown but will be the focus of future studies.
The PSM SH2 domain was found to be sucient for the association with PDGFR beta (Figure 2a) and it was found to abrogate the association between cellular PSM and PDGFR beta (Figure 1 ). This is not unexpected in the absence of other PSM candidate domains for the interaction with receptor phospho-tyrosine (Riedel et al., 1997) . These experiments were only feasible by immunoprecipitation with PDGFR beta antibody followed by immunoblotting with PSM antibody but not in the inverse order. This is due to the anity of the PSM antibody to the SH2 domain which would interfere with competition of the PSM SH2 domain peptide in the immunoprecipitation step (Figure 1 ). In addition, the related SH2-B beta had been shown to associate with activated PDGFR and the SH2 domain was shown to be necessary and sucient for this association by mutant analysis (Rui and Carter-Su, 1998 ). In the same study phosphorylation of SH2-B beta was observed in response to PDGF on tyrosine and likely serine and threonine (Rui and Carter-Su, 1998) . It is possible that PSM is similarly phosphorylated in response to PDGF-BB which remains to be determined.
To learn more about the role of PSM as a mitogenic signaling mediator we investigated its interaction with other receptor tyrosine kinases. In addition to the demonstrated association with PDGFR beta and the earlier reported associations with IR and IGF-IR (Riedel et al., 1997; Wang and Riedel, 1998; Kotani et al., 1998) , we found the PSM SH2 domain to associate with activated hepatocyte (Met), ®broblast, and nerve (Trk A), but not with epidermal growth factor receptors (Figure 3 ). APS and SH2-B have independently been implicated as substrates of Trk nerve growth factor receptors TrkB/C, and TrkA, respectively (Qian et al., 1998; Rui et al., 1999a) . When combined with the reported association of SH2-B with the FceRI receptor (Osborne et al., 1995) and of SH2-B beta with JAK2 in response to growth hormone stimulation (Rui et al., 1997) , the existing data suggest a role for PSM downstream of growth regulating receptors (van der Geer et al., 1994) , compatible with a putative role of PSM as a general mitogenic mediator. In the PDGFR beta signaling pathway PSM appears not to control the PI3K or MAP kinase signaling cascades since cell-permeable PSM SH2 domain peptides which inhibit PSM-PDGFR beta association in vitro (Figure 1 ) and mitogenesis in vivo (Figure 4 ) did not aect PI3K or MAP kinase activity (data not shown). The signaling pathway employed in the mitogenic responses to PSM has not been identi®ed yet which will be a premier focus of future studies (Rui et al., 1999b) .
The homologous insulin/IGF-I receptor major tyrosine autophosphorylation sites at aa 960/950 and aa 1322/1316 have been implicated in PSM SH2 domain binding (Wang and Riedel, 1998) . No clear consensus sequence has been identi®ed between the putative PSM binding sites of these receptors when compared with the implicated sequences around PDGFR beta aa 740. The PSM binding sites of the other receptor tyrosine kinases shown in Figure 3 are still unknown. The insulin receptor regions that are involved in the interaction with PSM are still being investigated, since point mutations in the activation loop, which, however aects many functions of the IR kinase, have also been shown to interfere with binding to the PSM SH2 domain (Kotani et al., 1998) .
To test the putative mitogenic role of PSM directly we employed three independent experimental strategies to interfere with cellular PSM function or increase cellular PSM levels. Initially, we microinjected the GST-PSM SH2 domain fusion protein to test its impact on PDGF-BB-and insulin-mediated mitogenesis in NIH3T3 ®broblasts. The high fusion protein concentration in the injected cells is expected to exert a dominant-negative eect on cellular PSM function (Gotoh et al., 1995; Northrop et al., 1996) . The observed reduction in DNA synthesis, in response to all tested stimuli suggests a positive, stimulatory role of cellular PSM in the involved mitogenic signaling pathway (Figure 4) . The observed reduction in DNA synthesis was speci®c for the PSM SH2 domain since a control Crk SH2 domain did not exert a signi®cant eect (Figure 4) . Experiments with IGF-I were not conclusive and have not been included. Experiments with cell-permeable PSM SH2 domain peptides did, however, demonstrate a dose-dependent inhibition of PDGF-BB-, IGF-I-, and insulin-mediated DNA synthesis (not shown) comparable to the results shown in Figure 4 .
The putative role of the PSM amino terminal Prorich region was tested in a synthetic cell-permeable fusion peptide with a 16 aa fragment of the Drosophila antennapedia homeodomain protein which mediates the eective transfer of fusion peptides across the cell membrane (Prochiantz, 1996) . We con®rmed transfer with biotinylated peptides which entered the cell cytoplasm in a peptide dose-responsive fashion (Table  1) . A tyrosine-phosphorylated, cell-permeable Grb2 binding peptide based on EGF receptor sequences was shown to speci®cally block the mitogenic response to PDGF and EGF but not to FGF, demonstrating that selective pathways are inhibited by this approach (Williams et al., 1997) . Activation of the MAP kinase cascade was inhibited in response to up to 10 ng/ml but not to higher 50 ng/ml EGF concentrations, suggesting that the peptide does not exert an excessive inhibitory function (Williams et al., 1997) . With this approach the IGF-I-and PDGF-BB-stimulated mitogenic responses were essentially eliminated with increasing concentration of PSM Pro-rich fusion peptide in a dose-responsive fashion whereas the EGF response remained unaected ( Figure 5 ). In particular, the mitogenic response to IGF-I was already abolished at somewhat lower peptide doses when compared to the PDGF-BB response. In contrast, the mitogenic response to insulin was greatly reduced but not completely abolished even at the highest peptide dose.
The PDGF-BB and IGF-I responses were tested in normal NIH3T3 ®broblasts in contrast to the insulin mitogenic response which was assayed in IR overexpressing NIH3T3 cells since it was not observable in normal NIH3T3 cells. This also applies to the PSM over-expression experiment shown in Figure 6b . Given that the same concentration range of fusion peptide has been used for each peptide hormone, the elevated IR receptor levels may explain the observation that the mitogenic insulin signal is not completely abolished even at the highest peptide dose. In contrast, the PDGF-BB and IGF-I mitogenic signals were completely abolished, which are based on the lower, normal cellular receptor levels. Control cell-permeable peptides did not exhibit any signi®cant interference with any mitogenic response and demonstrated that the observed inhibition is dependent on the presence of the PSM Pro-rich region ( Figure 5 ). In addition, we have tested a cell-permeable fusion peptide with a 16 aa fragment of the amino terminal Grb10 Pro-rich region which failed to aect PDGF-BB-mediated DNA synthesis (Wang et al., 1999) in contrast to the PSM Pro-rich region ( Figure 6 ). Consequently, a PSM-speci®c eect is observed in this assay which is not shared by any other Pro-rich region. Signi®cant speci®city has been reported for the interaction between Pro-rich sequence motifs and SH3 domains (Sparks et al., 1996) which is also suggested by our observations.
Since the elevated concentration of the cell-permeable fusion peptide is expected to result in a dominantnegative eect, our results are consistent with a stimulatory role of the PSM Pro-rich region in PDGF-BB, IGF-I and insulin, but not in EGF action. This is compatible with a role of PSM as a mitogenic signaling adapter that may involve its SH2 and Pro-rich domains to form a signaling complex between an activated receptor tyrosine kinase and an unknown SH3 domain mediator. The role of PSM in EGF action is still controversial. We have not observed any association of the PSM SH2 domain with the EGF receptor (Figure 3 ) or any evidence for PSM participation in the mitogenic response to EGF (Figures 5 and 6b) . However, in response to EGF, serine and threonine, but not tyrosine phosphorylation of the related SH2-B beta has been observed (Rui and Carter-Su, 1998) , which remains to be correlated with a possible function in EGF action. In the example of the signaling mediator Grb10 a similar phosphorylation pattern was reported in conjunction with the original discovery of the mediator (Ooi et al., 1995) . Still, a role in EGF action has not been established for Grb10 and remains to be demonstrated.
A stimulatory role for PSM in PDGF-BB, IGF-I, and insulin, but not in EGF-mediated-mitogenesis was directly shown by PSM cDNA expression from an ecdysone-regulated PSM expression plasmid. With this system the range of adjustable expression levels in cultured cells or in whole experimental mice, and the lack of basal expression surpassed tetracycline-based expression systems in a direct comparison . Activators have few, if any side eects and no toxicity at functional doses in vivo . Stimulation of DNA synthesis was ecdysone doseresponsive with the highest level observed for PDGF-BB at sixfold over background levels (Figure 6b) . The PSM-mediated mitogenesis correlated with increased PSM expression levels that had been determined by immunoblotting (Figure 6a ). Proper quanti®cation of protein expression levels based on immunoblots is dicult and Figure 6a may over-emphasize the level of expressed PSM when compared to normal cellular levels. An eect of PSM on DNA synthesis was already observed at small over-expression levels which double total cellular levels and the eect was found to increase in a PSM dose-responsive fashion (Figure 6 ). Observations have been reported for SH2-B beta that can be compared with regard to over-expression versus dominant-negative experimental strategies. An increase in nerve growth factor receptor (TrkA)-mediated neurite outgrowth was shown for SH2-B beta over-expression levels (Rui et al., 1999a) which substantially surpasses the PSM expression levels observed in our study. In comparison, a putatively dominant-negative form of SH2-B beta inhibited neurite outgrowth, suggesting that substantial SH2-B overexpression and dominant-negative strategies result in opposing physiologic responses (Rui et al., 1999a) . Similarly, in our hands interference by dominantnegative PSM domains (Figures 4 and 5 ) as well as PSM over-expression ( Figure 6 ) resulted in consistent and dose-dependent but opposing eects on DNA synthesis.
The PSM antiserum we employed had been raised against the SH2 domain and the adjacent short carboxyl terminal sequence and should recognize cellular PSM and additional variants that share the SH2 domain. We have typically observed one major protein band that associated with PDGFR beta (Figure 1 ) and IR or IGF-IR as shown earlier (Wang and Riedel, 1998) . It is unknown how many variant forms of PSM may exist and which ones may be expressed in the employed ®broblasts. cDNA expression experiments led to the detection of a PSM band of similar size as well as to a larger protein of an apparent migration of more than 120 kD (Figure 6a ). The nature of this larger band is unknown but it has sometimes been observed in untransfected cells and probably does not represent an over-expressed form of PSM. In this context earlier ®ndings about the related SH2-B beta should be noted with an antiserum that may exhibit speci®city for this variant. Several protein bands which dier in their modi®cation, including phosphorylation, have been reported ranging from about 80 kD up to about 100 kD in size for a predicted 670 aa protein coding region (Rui and Carter-Su, 1998 ). If we assume proportional migration characteristics for the predicted 756 aa PSM, protein bands would be expected ranging from 90 kD up to more than 110 kD, close to the apparent sizes we have actually observed in Figure 6a . A more detailed characterization of the PSM/SH2-B forms and their migration and modi®cation is beyond the focus of this report and will be the topic of future studies.
The ®ndings presented in this study support a positive, stimulatory role of PSM as a cellular partner of the PDGF beta, IGF-I, and insulin receptors based on several independent dominant-negative as well as positive experimental strategies. Since cell lines which stably over-express PSM are not yet available, we used a dominant-negative form of PSM to obtain ®rst evidence about a potential role in the transformed phenotype. When comparing the actin stress ®ber organization of normal BALB-3T3/A31 ®broblasts with a transformed and metastatic mutant line BALB-3T3/A31/M, a dramatic disorganization of the actin pattern is observed (Figure 7) which correlates with the transformed phenotype (Zvibel and Raz, 1985) . Microinjection of the SH2 domain resulted in a reversion of the transformed phenotype and partial reorganization of the actin pattern for PSM but not for Grb10 in a direct comparison (Figure 7 ). These data do not yet demonstrate a role of PSM in cell transformation but suggest that it may participate in this mechanism and will encourage future studies to address this question by over-expression and additional anti-PSM strategies. The suggested role of PSM and related mediators in the mitogenic response of a variety of growth factor receptors point to a function as a candidate general mediator of mitogenesis. This may provide a target for strategies directed at interfering with malignant cell transformation.
Materials and methods
All experiments have been carried out repeatedly, involving duplicate measurements, and the error has been indicated in the ®gures where appropriate. Alternatively, representative immunoblots have been shown. Experiments are based on cDNA expression of mouse PSM/mSH2-B which diers from a putative splice variant form beta (Rui et al., 1997; Riedel et al., 1997) and on an antiserum which was raised against the SH2 domain and carboxyl terminal sequences of PSM which should recognize PSM variants that share this domain.
Antibodies and peptides
Rabbit polyclonal antibodies directed against p85 PI 3'-kinase, epidermal (EGF), hepatocyte (Met), ®broblast (FGF), and nerve (TrkA) growth factor receptor, or against the cytoplasmic domains of PDGFR beta, IGF-IR, or IR were obtained from Upstate Biotechnology, an alternative rabbit polyclonal antibody directed against the cytoplasmic domain of PDGFR beta from Santa Cruz Biotechnology (Figure 1) , monoclonal anti phospho-tyrosine antibody PY20 from Transduction Laboratories, mouse monoclonal BrdU antibody from Amersham, and horse-radish peroxidase-coupled anti-IgG antibody from Kirkegaard and Perry Laboratories. PSM antiserum was produced by Hazelton Research Products Inc. (Denver, PA, USA) in rabbits against a GST fusion protein containing the SH2 domain and carboxyl terminal sequences of mouse PSM (Riedel et al., 1997; Wang and Riedel, 1998 
GST fusion protein construct and protein puri®cation
A 529 bp cDNA insert encoding the PSM SH2 domain and downstream coding sequences was released from the pVP16 library plasmid at its NotI cloning site (Riedel et al., 1997) and inserted into the NotI cloning site of pGEX-4T-1 (Pharmacia). E. coli DH5 alpha were transformed and transcription was induced with 0.5 mM isopropyl-beta-Dthiogalactopyranoside. The expressed GST-PSM SH2 domain fusion and control GST protein were puri®ed on a glutathione agarose column (Pharmacia), eluted in 10 mM reduced glutathione in 50 mM Tris-HCl pH 8.0 and stored after addition of 10 mM dithiothreitol, 1 mM EDTA as described by the manufacturer.
Construction and expression of cell-permeable Grb10 SH2 domain fusion peptides Optimal E. coli codons were used in the design of expressed oligonucleotides which contained a 5'-trityl group for column puri®cation (Fisher Scienti®c). Oligonucleotides including the 16 aa cell membrane transfer sequence (RQI-KIWFQNRRMKWKK) of the antennapedia homeodomain (5'-GGC GGC AGC CAT ATG CGT CAG ATC AAA ATG TGG TTC CAG AAC CGT CGT ATG AAA TGG AAA AAA GGA TCC-3'; membrane transfer sequence with 5' NdeI and 3' BamHI sites) and (5'-CCC CAA GCT TCA CTT AAT TAA GAG CTC TTA CTG CCA AGA CGG CGG CGG CGG CGG CAG CGC CGG CGG AGA CGG GAA GGA TCC TTT TTT-3'; Pro rich sequence with 5' HindIII and 3' BamHI sites) were hybridized via a 12 nucleotide overlap and extended by mutually primed DNA synthesis. NdeI and HindIII restriction sites had been introduced at the 5' and 3' ends, respectively. A BamHI restriction site had been introduced at the 3' end of the membrane transfer sequence. The complete sequence was inserted into the NdeI and HindIII sites of plasmid pET 28a(+) (Novagen, WI, USA). This expression plasmid is based on the strong T7 transcriptional promoter, confers kanamycin resistance and expresses an amino terminal 6 aa His-tag peptide for puri®cation of the recombinant protein.
The PSM SH2 domain was ampli®ed between aa 525 and 624, using PCR primers (5'-TTA TTA GGA TCC TAT CCT TGG TTC CAC GGC ATG CTC-3') and (5'-TTA CGC AAG CTT TCA ATA GCT GAC AAG GAC AAC ATC ACT-3') which introduced a 5' BamHI site and a 3' HindIII site into the ®nal PCR product. The PCR product was digested with BamHI and HindIII, isolated by electrophoresis followed by electroelution, and inserted into the BamHI and HindIII sites of the pET 28a(+) construct. All recombinant plasmids were transformed, isolated and characterized by restriction and DNA sequence analysis. The plasmid containing the membrane transfer sequence fused to the PSM SH2 domain was introduced into E. coli expression host [BL21(DE3)] which carries the lacUV5 promoter for induction by 1 mM isopropyl-beta-D-thiogalactopyranoside (IPTG). Cells were grown in LB medium containing kanamycin (30 mg/ml) at 378C to a density of 0.2 ± 0.3 O.D. 600 . IPTG induction was carried out for 5 h before cells were harvested and re-suspended in 0.5 M Tris-HCl, pH 6.8. Cells were disrupted by French Press lysis (SLM Instruments, Inc.), centrifuged at 15 000 g and 48C for 20 min. The cleared lysate was analysed by 15% SDS ± PAGE. The cell-permeable PSM fusion peptide was puri®ed by anity chromatography on a Nickel column (Novagen, WI, USA) and eluted with 0.4 M imidazole in the presence of 6 M urea. The peptide was dialyzed using a molecular weight cut-o of 3.5 kD (Pierce, IL, USA). Precipitation was observed after dialysis, and the peptide was resolubilized by addition of 1% DMSO to a ®nal concentration of 0.1% in 50 mM Tris-HCl buer, pH 6.8. The protein concentration was determined by Bradford analysis and the peptide was stored for several months at 48C.
cDNA expression
A cDNA containing the complete protein coding region of mouse PSM was assembled from the original lambda UniZap XR (Stratagene) phage clones (Riedel et al., 1997) and inserted into the multiple cloning site region of plasmid pIND (Invitrogen). The proper ligation product was con®rmed by restriction and DNA sequence analysis. This plasmid carries a heat shock transcriptional promoter and ecdysone response elements to allow ecdysone dose-dependent regulation of PSM expression. Ponasterone A (Invitrogen), an ecdysone analog was used in all experiments. The expression system employs a second plasmid pVgRXR for the expression of the ecdysone receptor from a cytomegalovirus transcriptional promotor which was cotransfected at the same concentration. Subcon¯uent NIH3T3 or baby hamster kidney (BHK) ®broblasts were rinsed with serum-and antibiotic-free medium and incubated for 5 h at 378C in 1 ml to which a transfection mix containing 1 mg of each plasmid and 10 ml Lipofectamine had been added according to the instructions of the manufacturer (Life Technologies, Gaithersburg, MD, USA). One ml of complete culture medium was added, cells were incubated for 14 h, and subsequently for 5 h in fresh complete medium. The ecdysone analog ponasterone A was added at various concentrations as indicated in the ®gure for 24 h. For protein analysis by SDS ± PAGE and immunoblotting cells were cultured in fresh complete medium for an additional 24 h in the presence of ponasterone A before they were lysed. Alternatively, for subsequent mitogenic analysis cells were treated as described below.
Thymidine incorporation and interference by cell-permeable peptides
To subsequently assay for DNA synthesis cells were starved for 20 h in the presence of ponasterone A. Subsequently IGF-I, insulin, or EGF at 100 ng/ml or PDGF-BB at 25 ng/ ml, were added for 18 h, and ®nally 0.5 mCi [methyl-3 H thymidine] at 3 Tbq/mmol for 5 h. Cells were rinsed three times in ice-cold PBS and incubated in 10% trichloroacetic acid for 1 h at 48C. Cells were rinsed and 0.5 ml of 0.2 N NaOH, 0.1% SDS were added at 378C for 1 h. The pH was neutralized by addition of 0.5 ml 2 M Tris pH 6.8, and 2 ml of cocktail (ScintiSafe Econo-1, Fisher) were added before the incorporated radioactivity was quanti®ed by liquid scintillation spectroscopy.
To test the eect of cell-permeable peptides on DNA synthesis, NIH3T3 ®broblasts were starved for 20 h. Growth factors were added at the concentrations indicated above in addition to cell-permeable peptides at the concentrations indicated in the ®gure for 18 h as mCi. [methyl-3 H thymidine] was added for 5 h and the incorporated radioactivity was determined as described above. Normal ®broblasts were used for all growth factors except for insulin which did not result in a response (not shown). Insulin stimulation was tested in IR over-expressing ®broblasts (Blakesley et al., 1996) .
Microneedle injection and BrdU incorporation
IR over-expressing NIH3T3 ®broblasts (Blakesley et al., 1996) were grown on 12-mm coverslips and starved for 24 h in serum-free medium. 150 cells were microinjected for each condition with about 10 714 1 GST fusion protein with the PSM or Crk SH2 domain at 3 mg/ml by using glass microcapillaries (Eppendorf) in 5 mM NaPO 4 , 100 mM KCl, pH 7.4 (Sasaoka et al., 1994) . Two hours later cells were stimulated with 25 ng/ml PDGF-BB, 100 ng/ml insulin, or 10% fetal bovine serum for 16 h in the presence of 3'-bromo-5'-deoxyuridine (BrdU). Cells were ®xed in 90% ethanol, 5% acetic acid for 20 min at 228C and incubated with BrdU mouse monoclonal antibody for 1 h at 228C. Cells were stained with¯uoresceine-labeled donkey anti-mouse IgG antibody, mounted and indirect¯uorescence was analysed with an Axiovert¯uorescence microscope (Zeiss).
Cell culture, peptide interference, immunoprecipitation and immunoblotting
Normal ®broblasts or cell lines over-expressing various wild-type or mutant receptors were used as indicated in the ®gure legends. Cells were incubated in serum-free medium for 16 h and stimulated with 25 ng/ml PDGF-BB, 100 ng/ ml IGF-I, or 100 ng/ml insulin for 15 min. Cells were rinsed twice with PBS and harvested in ice-cold lysis buer containing 50 mM HEPES pH 7.4, 1% Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 10 mM NaF, 100 mM Na 3 VO 4 , 10 mM Na pyrophosphate, 10 mg/ml leupeptin, 10 mg/ml aprotinin and 1 mM PMSF. Proteins (typically 40 mg) were directly subjected to SDS ± PAGE or (typically 300 mg) were ®rst mixed with GST-PSM SH2 domain fusion protein, or antibodies directed against PSM, p85 PI3K, PDGFR beta, IGF-IR, or IR for 2 h and coprecipitated with glutathione sepharose or protein A sepharose beads, respectively for 1 h. Phospho-peptides were mixed with the GST-PSM SH2 domain fusion protein to study their competition with receptor binding. Precipitates were washed with lysis buer, separated by SDS 8% PAGE and analysed by immunoblotting with the indicated speci®c antibodies using the ECL (Amersham) detection system (Hansen et al., 1996) .
Actin ®lament organization in normal and transformed BALB-3T3/A31 ®broblasts GST fusion proteins with the SH2 domains of PSM or Grb10 were microinjected into groups of 150 parental BALB-3T3/A31 control cells and into a (spontaneously mutated and selected) transformed and metastatic variant line Balb-3T3/A31/M (Zvibel and Raz, 1985) . Cells were cultured in 10% bovine calf serum and actin organization was evaluated after 24 h. Cells were permeabilized with 0.5% Triton X-100, ®xed with 3% formaldehyde and stained with rhodamine-conjugated phalloidin. Slides were mounted and¯uorescence was evaluated with an Axiovert uorescence microscope (Zeiss).
